High prevalence of drug-resistant tuberculosis, Republic of Lithuania, 2002

P Dewan, A Sosnovskaja, V Thomsen, J Cicenaite, K Laserson, I Johansen, E Davidaviciene, C Wells

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

BACKGROUND: Nations of the former Soviet Union have the world's highest reported levels of resistance to anti-tuberculosis drugs. We conducted the first national survey of anti-tuberculosis drug resistance in the Republic of Lithuania.

METHODS: We tested Mycobacterium tuberculosis isolates from all incident culture-positive pulmonary TB patients registered in 2002. New patients were those treated for <1 month with any first-line anti-tuberculosis drug (isoniazid [INH], rifampin [RMP], ethambutol, or streptomycin); previously treated patients were those treated for > or =1 month.

RESULTS: Of 1163 isolates, 475 (41%) were resistant to at least one first-line drug, and 263 (23%) were resistant to at least INH and RMP (MDR); this included 76/818 (9.3%) from new patients and 187/345 (54%) from previously treated patients. Of 52 MDR isolates randomly selected for extended testing at an international reference laboratory, 27 (51%, 95%CI 38-66) had resistance to pyrazinamide, 21 (40%, 95%CI 27-55) to kanamycin, and 9 (17%, 95%CI 8-30) to ofloxacin.

CONCLUSIONS: The prevalence of MDR-TB in Lithuania is among the world's highest. Among MDR-TB isolates, aminoglycoside and fluoroquinolone resistance were common. To combat drug-resistant TB, Lithuania has implemented the WHO global TB control strategy (DOTS), and is developing an MDR-TB treatment program (DOTS-Plus).

OriginalsprogEngelsk
TidsskriftInternational Journal of Tuberculosis and Lung Disease
Vol/bind9
Udgave nummer2
Sider (fra-til)170-4
Antal sider5
ISSN1027-3719
StatusUdgivet - feb. 2005

Fingeraftryk Dyk ned i forskningsemnerne om 'High prevalence of drug-resistant tuberculosis, Republic of Lithuania, 2002'. Sammen danner de et unikt fingeraftryk.

Citationsformater